目的：评估贝伐单抗和卡培他滨的联合方案在老年转移性结直肠癌(metastatic colon or rectal cancer，mCRC)患者一线治疗中的疗效和安全性。方法：收集2013年1月至2016年12月入住首都医科大学附属北京友谊医院76例使用贝伐单抗(5~7.5 mg/kg，d1，q3w)联合卡培他滨(1 000~1 250 mg/m2，bid，d1~14，q3w)一线治疗老年mCRC的病例进行分析，分析疗效及不良反应(adverse events，AE)。结果：经贝伐单抗联合卡培他滨方案治疗，患者总体有效率为36%，疾病控制率为73%；中位无进展生存期和总生存期分别为10.6个月和18.2个月；39例(51%)患者发生3/4级AE，最常见的为手足综合征(18%)、腹泻(10%)和深静脉血栓形成(7%)；4名患者因治疗相关的AE死亡。结论：对于不适合接受多药联合化疗的老年患者，贝伐单抗联合卡培他滨是一种有效的治疗选择。
Effect and safety of bevacizumab combined with capecitabine in the treatment of elderly patients with metastatic colorectal cancer
Objective: To evaluate the efficacy and safety of bevacizumab and capecitabine in the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC). Methods: A total of 76 elderly patients with metastatic colorectal cancer first-line treated with (5–7.5 mg/kg, d1, q3w) combined with capecitabine (1 000–1 250 mg/m2, bid, d1–14, q3w) between January 2013 and December 2016 were collected. The efficacy and adverse events (AEs) were carefully analyzed. Results: After treated with bevacizumab combined with capecitabine, the overall effective rate was 36% and the disease control rate was 73%. The median progression-free survival and overall survival were 10.6 months and 18.2 months, respectively; 39 patients (51%) developed grade 3 and 4 AE, the most common were hand-foot syndrome (18%), diarrhea (10%) and deep vein thrombosis (7%); four patients died due to treatment-related adverse events. Conclusion: For elderly mCRC patients who are not eligible for multidrug chemotherapy, bevacizumab combined with capecitabine is an effective treatment option.